Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Prospective, Non-Randomized, Open-Label, Active-Controlled Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury

NCT07347938 is registered in ClinicalTrials.gov with Zhuhai Trinomab Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT07347938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07347938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Prospective, Non-Randomized, Open-Label, Active-Controlled Phase 4 Study to Evaluate the Effectiveness and Safety of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Lead sponsor
Zhuhai Trinomab Pharmaceutical Co., Ltd.
Phase
Observational
Overall status
Recruiting
Start date
January 14, 2026
Completion date
March 31, 2029
Enrollment
6,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tetanus